Incyte Corp SEC Filings

Incyte Corporation (INCY) filed a Form 4 disclosing an insider sale. A director reported selling 187,500 shares of common stock on 11/10/2025 at a price of $105.46 per share. Following this transaction, the reporting person beneficially owns 329,646 shares, held directly.

The filing notes that this total includes 73,486 shares issuable from previously reported RSUs and earned performance shares that have not yet vested. No derivative securities were reported in Table II for this transaction. This is a routine insider ownership update and does not by itself indicate changes in company operations or strategy.

Incyte Corp (INCY): Form 4 insider activity. The company’s EVP & Chief Medical Officer reported option exercises and a same‑day sale on 11/05/2025.

The executive exercised options for 1,194 shares at $83.83, 2,995 shares at $95.76, and 1,044 shares at $95.76, then sold 5,233 shares at $102.20. Following these transactions, the executive beneficially owns 102,886 shares directly.

Footnotes note that 100,327 shares are issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. The exercised options were from grants that became exercisable per their original vesting schedules.

Incyte (INCY) insider activity: The company’s EVP & General Counsel reported a same‑day option exercise and sale on 11/04/2025. He exercised 598 employee stock options at $58.06 per share and sold 598 common shares at $101.36 per share.

Following these transactions, he directly owned 26,569 common shares. He also held 13,765 derivative securities (employee stock options) after the activity. In addition, the filing notes 25,913 shares of common stock are issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

Incyte Corp (INCY) reported an insider transaction on Form 4. The company’s EVP, Head of Incyte Intl, sold 3,074 shares of common stock on 11/03/2025 at $94.02 per share.

Following the sale, the reporting person beneficially owned 29,241 shares directly. This figure includes 26,167 shares issuable pursuant to previously reported RSUs that have not vested.

Incyte reported stronger Q3 results, with total revenue of $1.366 billion, up from $1.138 billion a year ago. Net income rose to $424.2 million (diluted EPS $2.11) from $106.5 million ($0.54). Year to date, revenue reached $3.634 billion and net income was $987.4 million, a sharp improvement from a loss in the prior year.

Growth was broad-based: JAKAFI revenue was $791.1 million, OPZELURA $188.0 million, and new contributions included NIKTIMVO at $45.8 million and ZYNYZ at $22.7 million. Royalty revenue increased to $171.1 million, led by JAKAVI royalties of $125.6 million. Milestone and contract revenue was $45.0 million.

Operating expense trends were favorable. R&D for the quarter was $506.6 million versus $573.2 million, and cost of product revenues was $99.0 million. For the nine months, results also reflect a $242.3 million contract dispute settlement benefit tied to resolved JAKAFI royalties with Novartis and a 50% reduction in the ongoing U.S. JAKAFI royalty rate starting January 1, 2025. Cash and cash equivalents were $2.455 billion, with marketable securities of $474.8 million. Shares outstanding were 196,322,703 as of October 21, 2025.

Incyte Corporation filed a current report stating that it has released financial results for its third fiscal quarter ended September 30, 2025. The company furnished the full text of its earnings press release as Exhibit 99.1, dated October 28, 2025. The report is presented as routine financial disclosure under the item covering results of operations and financial condition.

Incyte (INCY) reported an insider transaction by its EVP & General Counsel. On 10/15/2025, the officer exercised 277 employee stock options at a $64.25 exercise price and sold 277 shares of common stock at $85.13.

Following the transactions, the officer beneficially owned 26,569 shares directly, which includes an aggregate of 25,913 shares issuable from previously reported unvested RSUs and earned performance units. Derivative securities beneficially owned after the transactions totaled 9,161 options. The reported option grant expires on 07/14/2034 and vests in installments as disclosed.

Sheila A. Denton, EVP & General Counsel of Incyte Corp (INCY), reported multiple transactions on 10/02/2025 and 10/03/2025. She exercised employee stock options for 599 shares at an exercise price of $58.06 and acquired 599 common shares via that exercise. Concurrently, she sold a series of shares: 599 at $87.65, 3,130 at $86.28, and 3,501 at $85.54, reducing her direct common stock holdings to 26,569 shares. The filing notes 3,130 shares were withheld to satisfy tax obligations and that 25,913 shares remain issuable under previously reported restricted stock units and earned performance units that have not vested. After the reported activity, she holds 14,363 option-based derivative securities and 26,569 direct common shares.

Incyte Corporation (INCY) submitted a Form 144 notifying a proposed sale of 3,501 restricted shares valued at $299,464.34, to be executed through Morgan Stanley Smith Barney LLC on 10/03/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 10/02/2025 and the filer reports 195,276,145 shares outstanding for the issuer.

The filing lists prior insider sales by Sheila Denton over the past three months totaling 6,165 shares across seven transactions, with gross proceeds shown for each sale (largest single prior sale: 3,330 shares for $232,633.80 on 07/15/2025). The notice includes the standard signature representation that the seller has no undisclosed material adverse information and names the executing broker and address.